12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IMO-3100: Completed Phase II enrollment

Idera completed enrollment of 44 patients in a placebo-controlled, double-blind, U.S. Phase II trial evaluating 0.16 and 0.32 mg/kg subcutaneous IMO-3100 once weekly for 4 weeks.

Last July, FDA verbally informed the company...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >